These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 20079692

  • 1. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
    Revermann M.
    Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.
    Imig JD.
    Cardiovasc Drug Rev; 2006 Apr; 24(2):169-88. PubMed ID: 16961727
    [Abstract] [Full Text] [Related]

  • 5. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
    Xu X, Zhang XA, Wang DW.
    Adv Drug Deliv Rev; 2011 Jul 18; 63(8):597-609. PubMed ID: 21477627
    [Abstract] [Full Text] [Related]

  • 6. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
    Ni GH, Chen JF, Chen XP, Yang TL.
    Pharmazie; 2011 Mar 18; 66(3):153-7. PubMed ID: 21553642
    [Abstract] [Full Text] [Related]

  • 7. Epoxyeicosatrienoic acid pathway in human health and diseases.
    Bellien J, Joannides R.
    J Cardiovasc Pharmacol; 2013 Mar 18; 61(3):188-96. PubMed ID: 23011468
    [Abstract] [Full Text] [Related]

  • 8. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.
    Duflot T, Roche C, Lamoureux F, Guerrot D, Bellien J.
    Expert Opin Drug Discov; 2014 Mar 18; 9(3):229-43. PubMed ID: 24490654
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
    Pallàs M, Vázquez S, Sanfeliu C, Galdeano C, Griñán-Ferré C.
    Biomolecules; 2020 May 01; 10(5):. PubMed ID: 32369955
    [Abstract] [Full Text] [Related]

  • 13. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning.
    Gauthier KM, Yang W, Gross GJ, Campbell WB.
    J Cardiovasc Pharmacol; 2007 Dec 01; 50(6):601-8. PubMed ID: 18091575
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy.
    Romashko M, Schragenheim J, Abraham NG, McClung JA.
    Trends Pharmacol Sci; 2016 Nov 01; 37(11):945-962. PubMed ID: 27633970
    [Abstract] [Full Text] [Related]

  • 16. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.
    Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB.
    Am J Physiol Renal Physiol; 2011 Oct 01; 301(4):F765-72. PubMed ID: 21753077
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor.
    Podolin PL, Bolognese BJ, Foley JF, Long E, Peck B, Umbrecht S, Zhang X, Zhu P, Schwartz B, Xie W, Quinn C, Qi H, Sweitzer S, Chen S, Galop M, Ding Y, Belyanskaya SL, Israel DI, Morgan BA, Behm DJ, Marino JP, Kurali E, Barnette MS, Mayer RJ, Booth-Genthe CL, Callahan JF.
    Prostaglandins Other Lipid Mediat; 2013 Oct 01; 104-105():25-31. PubMed ID: 23434473
    [Abstract] [Full Text] [Related]

  • 18. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
    Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM.
    Am J Physiol Heart Circ Physiol; 2008 Nov 01; 295(5):H2128-34. PubMed ID: 18835921
    [Abstract] [Full Text] [Related]

  • 19. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.
    Ghosh S, Chiang PC, Wahlstrom JL, Fujiwara H, Selbo JG, Roberds SL.
    Basic Clin Pharmacol Toxicol; 2008 May 01; 102(5):453-8. PubMed ID: 18312493
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.